Few ingredients have shaped the cholesterol supplement market as significantly as red yeast rice. For more than two decades, products containing Monacolin K have been widely used in cholesterol support formulations across Europe, North America and Asia.
Until recently, hundreds of supplements globally relied on red yeast extracts as their primary active ingredient, positioning them as “natural alternatives” to pharmaceutical statins.
However, current regulatory developments affecting monacolins from red yeast rice, including the European Food Safety Authority's conclusion that these compounds may be unsafe at any intake level, are prompting a reassessment of one of the category’s most established ingredients.1
This follows earlier action by the European Commission that restricted the permitted levels of Monacolin K in food supplements, reflecting concerns around its pharmacological activity and potential safety risks.1
Taken together, these developments signal more than incremental regulatory change. They point to a broader structural shift within the cholesterol supplement category, compelling brands and nutraceutical developers to rethink how cardiometabolic products are formulated.2
Pernille Butho Tørnes, Head of Product Management at ProBiotix Health, takes up the story.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.